Could lead to a permanent treatment strategy in the //future . A promising study published in Science Advances suggests that a natural RNA (a genetic messenger that helps cells ...

WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver ...

The Oligonucleotide Therapeutics Society (OTS) is pleased to announce the 21st Annual OTS Meeting, scheduled for October ...

Nucleic acid therapies offer targeted treatment for genetic diseases, but delivery remains a key hurdle. Explore how advances ...

In eukaryotic cells, the nucleolus is the central site for ribosome biogenesis. It is composed of distinct subcompartments: fibrillar center (FC), dense fibrillar component (DFC), periphery of DFC ...

Meet 12 biotech companies with promising genetic disease therapies that successfully closed funding rounds recently.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the second quarter ended June 30, 2025.

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

In July 2025, CereMark Pharma LLC conducted a clinical trial to evaluate the safety and efficacy of [F-18]Flornaptitril-PET (F-18 FNT-PET) for the prediction of clinical progression of Mild Cognitive ...

Adrian R. Krainer has been awarded the 2025 Heinrich Wieland Prize for his pioneering RNA research that led to the ...